Plaque Psoriasis 
The MD Magazine Plaque Psoriasis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.


FDA Approves Brodalumab for Plaque Psoriasis
The FDA has approved brodalumab for moderate-to-severe plaque psoriasis in patients who are eligible for systemic therapy or phototherapy and who have failed to respond or stopped responding to other systemic therapies.
Though air pollution has previously been associated with elevated rates of atopic dermatitis (AD), the reason for that correlation remained mostly a mystery until last week.
Nearly one-third of patients with plaque psoriasis will also be diagnosed with psoriatic arthritis. While somewhat common, this diagnosis requires a different approach to care in order to help patients better manage their symptoms.
With plaque psoriasis becoming an increasingly common condition providers are able to more easily identify the condition than they had in the past. Looking for red scaling plaques, and thickened skin, as well as asking questions can get doctors the answers they need. In rare cases skin biopsies are also performed.
The days of patients with plaque psoriasis being treated with tar and special lights are fading as new agents, especially oral agents, are being developed.
For many patients, chronic idiopathic urticaria can be a debilitating condition affecting them at all hours of the day and making living with the condition very difficult. Because of this, the need for newer, more effective treatments is driving the field forward at a rapid pace.
Approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease, ustekinumab appeared to benefit patients with severe atopic dermatitis (AD) in a small study seeking to correlate its immunologic effects with clinical efficacy.
A recent review of current research on atopic dermatitis (AD) treatments found that a clearer understanding of the pathogenesis of the phenotypes involved in the disease will lead to advances in new therapies.
Patients with active psoriatic arthritis treated with secukinumab for 2 years in the FUTURE-1 trial experienced sustained decreases in disease activity and symptoms, leading to improvements in physical function and quality of life.

Most Popular


$vacMongoViewPlus$ $vAR$